XZP-3287

DRUG2 trials

Sponsors

Sihuan Pharmaceutical Holdings Group Ltd., Xuanzhu Biopharmaceutical Co., Ltd.

Conditions

Advanced Breast CancerHealthyMetastasis Solid Tumors

Phase 1

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Active, not recruitingNCT04539496

Sihuan Pharmaceutical Holdings Group Ltd.Advanced Breast Cancer, Metastasis Solid Tumors

Start: 2018-05-22End: 2025-12-31Updated: 2024-09-19

Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Xuanzhu Biopharmaceutical Co., Ltd.Healthy

Start: 2021-08-31End: 2021-12-31Target: 24Updated: 2021-07-27

Related Papers

Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial.

2025-10-08

Brain metastasis incidence with bireociclib in HR+/HER2- advanced breast cancer: Pooled analysis of BRIGHT-1 and BRIGHT-2 study.

Journal of Clinical Oncology2025-05-28

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

Nature Communications2025-04-091 citations

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications2025-02-273 citations

A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.

Journal of Clinical Oncology2023-06-012 citations